Difference between revisions of "CNS5:Medulloblastoma, WNT-activated"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[unchecked revision][unchecked revision]
(Created page with " ==Primary Author(s)*== __TOC__ ==Cancer Category/Type== Put your text here ==Cancer Sub-Classification / Subtype== Put your text here ==Definition / Description of Dise...")
 
Line 3: Line 3:
  
 
__TOC__
 
__TOC__
 +
 +
Lisa Lansdon, PhD, Children's Mercy Hospital, Kansas City
 +
 +
Midhat Farooqi, MD, Children's Mercy Hospital, Kansas City
  
 
==Cancer Category/Type==
 
==Cancer Category/Type==
Line 42: Line 46:
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
 
|-
 
|-
! Finding   !! Marker
+
!Finding!!Marker
 
|-
 
|-
|Positive (universal) || EXAMPLE CD1
+
|Positive (universal)||EXAMPLE CD1
 
|-
 
|-
|Positive (subset) || EXAMPLE CD2
+
|Positive (subset)||EXAMPLE CD2
 
|-
 
|-
|Negative (universal) || EXAMPLE CD3
+
|Negative (universal)||EXAMPLE CD3
 
|-
 
|-
|Negative (subset) || EXAMPLE CD4
+
|Negative (subset)||EXAMPLE CD4
 
|}
 
|}
  
Line 59: Line 63:
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
 
|-
 
|-
! Chromosomal Rearrangement !! Genes in Fusion (5’ or 3’ Segments) !! Pathogenic Derivative !! Prevalence
+
!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
 
|-
 
|-
|EXAMPLE t(9;22)(q34;q11.2) || EXAMPLE 3'ABL1 / 5'BCR || EXAMPLE der(22) || EXAMPLE 5%
+
|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 5%
 
|-
 
|-
|EXAMPLE t(8;21)(q22;q22) || EXAMPLE 5'RUNX1 / 3'RUNXT1 || EXAMPLE der(8) || EXAMPLE 5%
+
|EXAMPLE t(8;21)(q22;q22)||EXAMPLE 5'RUNX1 / 3'RUNXT1||EXAMPLE der(8)||EXAMPLE 5%
 
|}
 
|}
 
 
Line 76: Line 80:
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
 
|-
 
|-
! Chromosome Number !! Gain/Loss/Amp/LOH !! Region
+
!Chromosome Number!!Gain/Loss/Amp/LOH!!Region
 
|-
 
|-
|EXAMPLE 8 || EXAMPLE Gain || EXAMPLE chr8:0-1000000
+
|EXAMPLE 8||EXAMPLE Gain||EXAMPLE chr8:0-1000000
 
|-
 
|-
|EXAMPLE 7 || EXAMPLE Loss || EXAMPLE chr7:0-1000000
+
|EXAMPLE 7||EXAMPLE Loss||EXAMPLE chr7:0-1000000
 
|}
 
|}
 
 
Line 89: Line 93:
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
 
|-
 
|-
! Gene !! Mutation !! Oncogene/Tumor Suppressor/Other !! Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) !! Prevalence (COSMIC/TCGA/Other)
+
!Gene!!Mutation!!Oncogene/Tumor Suppressor/Other!!Presumed Mechanism (LOF/GOF/Other; Driver/Passenger)!!Prevalence (COSMIC/TCGA/Other)
 
|-
 
|-
| EXAMPLE TP53 || EXAMPLE R273H || EXAMPLE Tumor Suppressor || EXAMPLE LOF || EXAMPLE 20%
+
|EXAMPLE TP53||EXAMPLE R273H||EXAMPLE Tumor Suppressor||EXAMPLE LOF||EXAMPLE 20%
 
|}
 
|}
 
 
Line 97: Line 101:
 
{| class="wikitable sortable"
 
{| class="wikitable sortable"
 
|-
 
|-
! Type !! Gene/Region/Other
+
!Type!!Gene/Region/Other
 
|-
 
|-
| Concomitant Mutations || EXAMPLE IDH1 R123H
+
|Concomitant Mutations||EXAMPLE IDH1 R123H
 
|-
 
|-
| Secondary Mutations || EXAMPLE Trisomy 7
+
|Secondary Mutations||EXAMPLE Trisomy 7
 
|-
 
|-
|Mutually Exclusive || EXAMPLE EGFR Amplification
+
|Mutually Exclusive||EXAMPLE EGFR Amplification
 
|}
 
|}
  
Line 136: Line 140:
 
==References==
 
==References==
  
=== EXAMPLE Book ===
+
===EXAMPLE Book===
 +
 
 
#Arber DA, et al., (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.
 
#Arber DA, et al., (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.
  
=== EXAMPLE Journal Article ===
+
===EXAMPLE Journal Article===
 +
 
 
#Li Y, et al., (2001). Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28:220-221, PMID 11431691.
 
#Li Y, et al., (2001). Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28:220-221, PMID 11431691.
  
== Notes ==
+
==Notes==
 
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.
 
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

Revision as of 13:05, 20 September 2021

Primary Author(s)*

Lisa Lansdon, PhD, Children's Mercy Hospital, Kansas City

Midhat Farooqi, MD, Children's Mercy Hospital, Kansas City

Cancer Category/Type

Put your text here

Cancer Sub-Classification / Subtype

Put your text here

Definition / Description of Disease

Put your text here

Synonyms / Terminology

Put your text here

Epidemiology / Prevalence

Put your text here

Clinical Features

Put your text here

Sites of Involvement

Put your text here

Morphologic Features

Put your text here

Immunophenotype

Put your text here and/or fill in the table

Finding Marker
Positive (universal) EXAMPLE CD1
Positive (subset) EXAMPLE CD2
Negative (universal) EXAMPLE CD3
Negative (subset) EXAMPLE CD4

Chromosomal Rearrangements (Gene Fusions)

Put your text here and/or fill in the table

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence
EXAMPLE t(9;22)(q34;q11.2) EXAMPLE 3'ABL1 / 5'BCR EXAMPLE der(22) EXAMPLE 5%
EXAMPLE t(8;21)(q22;q22) EXAMPLE 5'RUNX1 / 3'RUNXT1 EXAMPLE der(8) EXAMPLE 5%

Characteristic Chromosomal Aberrations / Patterns

Put your text here

Genomic Gain/Loss/LOH

Put your text here and/or fill in the table

Chromosome Number Gain/Loss/Amp/LOH Region
EXAMPLE 8 EXAMPLE Gain EXAMPLE chr8:0-1000000
EXAMPLE 7 EXAMPLE Loss EXAMPLE chr7:0-1000000

Gene Mutations (SNV/INDEL)

Put your text here and/or fill in the tables

Gene Mutation Oncogene/Tumor Suppressor/Other Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) Prevalence (COSMIC/TCGA/Other)
EXAMPLE TP53 EXAMPLE R273H EXAMPLE Tumor Suppressor EXAMPLE LOF EXAMPLE 20%

Other Mutations

Type Gene/Region/Other
Concomitant Mutations EXAMPLE IDH1 R123H
Secondary Mutations EXAMPLE Trisomy 7
Mutually Exclusive EXAMPLE EGFR Amplification

Epigenomics (Methylation)

Put your text here

Genes and Main Pathways Involved

Put your text here

Diagnostic Testing Methods

Put your text here

Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)

Put your text here

Familial Forms

Put your text here

Other Information

Put your text here

Links

Put your links here

References

EXAMPLE Book

  1. Arber DA, et al., (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.

EXAMPLE Journal Article

  1. Li Y, et al., (2001). Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28:220-221, PMID 11431691.

Notes

*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.